Metraipolis › archive › dc_f563fd1764cf

Refractory severe type B insulin resistance treated with daratumumab — Europe PMC PMID:42211865

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42211865
DOI
10.1210/jcemcr/luag145
License (as archived)
solo-consultazione
Archived
2026-11-01T06:08:51.976Z
SHA-256 of the archived text
5d228a178ebcf6b61dc042e69ea69bbde38df96f7f958230b439dfe070900738
Stable URL of this page
https://metraipolis.com/documento/dc_f563fd1764cf

How to cite

Refractory severe type B insulin resistance treated with daratumumab — Europe PMC PMID:42211865 — Europe PMC (en), https://europepmc.org/article/MED/42211865 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_f563fd1764cf (Metraipolis archive dc_f563fd1764cf, sha256 5d228a178ebcf6b61dc042e69ea69bbde38df96f7f958230b439dfe070900738)
BibTeX
@misc{dcf563fd1764cf,
  title = {Refractory severe type B insulin resistance treated with daratumumab — Europe PMC PMID:42211865},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42211865},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_f563fd1764cf; sha256 5d228a178ebcf6b61dc042e69ea69bbde38df96f7f958230b439dfe070900738},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42211865. Agents can read the archived copy with the MCP tool read_document.